Clinical Trial Update: Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and systemic safety of netarsudil at 0.01%, 0.02%, and 0.04% versus placebo in open-angle glaucoma or ocular hypertension …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• Netarsudil (netarsudil)

Snippet

Sponsor: Aerie Pharmaceuticals | Conditions: Open Angle Glaucoma, Ocular Hypertension | Phase 2 | Status: COMPLETED | Results posted: 2020-10-19